NilotinibIn the First-Line Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia in Chronic Phase

被引：0
作者：
Karly P. Garnock-Jones
机构：
[1] Adis,
[2] a Wolters Kluwer Business,undefined
来源：
Drugs | 2011年 / 71卷
关键词：
Imatinib; Chronic Myeloid Leukaemia; Nilotinib; Anagrelide; Major Molecular Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Nilotinib is an effective first-line treatment for newly diagnosed Philadelphia chromosome-positive chronic myeloid leukaemia (CML) in chronic phase. It is an aminopyrimidine-based, high-affinity inhibitor of the tyrosine kinase activity of BCR-ABL. It thus decreases ABL-associated cell proliferation and kinase autophosphorylation.
引用
收藏
页码：1579 / 1590
页数：11
相关论文
共 47 条
[1]  
Weisberg E(2006)AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL Br J Cancer 94 1765-9
[2]  
Manley P(1999)The biology of chronic myeloid leukemia N Engl J Med 341 164-72
[3]  
Mestan J(2008)Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression Cancer Res 68 9809-16
[4]  
Faderl S(2009)Chronic myelogenous leukemia: ESMO clinical recommendations for diagnosis, treatment and follow-up Ann Oncol 20 iv105-7
[5]  
Talpaz M(2009)International randomized study of interferon vs STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib [abstract no 1126] Blood 114 462-8
[6]  
Estrov Z(2010)First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib [online] J Hematol Oncol 3 47-59
[7]  
Mahon FX(2010)Chronic myeloid leukemia 2010: where are we now and where can we go? Hematology Am Soc Hematol Educ Program 2010 122-41
[8]  
Hayette S(2008)Nilotinib Drugs 68 449-7
[9]  
Lagarde V(2005)Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl Cancer Cell 7 129-53
[10]  
Baccarani M(2005)AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia Clin Cancer Res 11 4941-203
12345